In summary, MFYS exerts its therapeutic effects on membranous nephropathy in the PHN model by promoting Treg differentiation and reducing rat IgG-mediated podocyte injury, which is associated with the activation of the PI3K/AKT signaling pathway (Fig. 11). The gene discussed is AKT1; the disease is membranous glomerulonephritis.